The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trials of cetuximab (CX) plus cisplatin (CDDP), 5-fluorouracil (5-FU) and radiation (RT) in immunocompetent (ECOG 3205) and HIV-positive (AMC045) patients with squamous cell carcinoma of the anal canal (SCAC): Safety and preliminary efficacy results.
Madhur Garg
No relevant relationships to disclose
Jeanette Y Lee
No relevant relationships to disclose
Lisa A. Kachnic
No relevant relationships to disclose
Paul J. Catalano
No relevant relationships to disclose
David H. Henry
No relevant relationships to disclose
Timothy Patrick Cooley
No relevant relationships to disclose
Lee Ratner
No relevant relationships to disclose
William Wachsman
No relevant relationships to disclose
David Michael Aboulafia
No relevant relationships to disclose
Al Bowen Benson
No relevant relationships to disclose
Joel Palefsky
No relevant relationships to disclose
Richard Whittington
No relevant relationships to disclose
Ronald T. Mitsuyasu
No relevant relationships to disclose
Joseph A. Sparano
No relevant relationships to disclose